Loading…
Gain Therapeutics, Inc. is projected to rise to $1.76 by 2027, a +4% move from its current price of $1.68. GANX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.62 | $1.68 | $1.75 | -0.04% |
| Aug 6 | $1.59 | $1.68 | $1.77 | -0.08% |
| Aug 7 | $1.57 | $1.68 | $1.79 | -0.11% |
| Aug 8 | $1.55 | $1.68 | $1.81 | -0.15% |
| Aug 9 | $1.54 | $1.68 | $1.83 | -0.19% |
| Aug 10 | $1.52 | $1.68 | $1.84 | -0.23% |
| Aug 11 | $1.51 | $1.68 | $1.86 | -0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.51 | $1.68 | $1.86 | -0.26% |
| Week 2 | $1.45 | $1.67 | $1.93 | -0.53% |
| Week 3 | $1.40 | $1.67 | $1.99 | -0.79% |
| Week 4 | $1.35 | $1.66 | $2.04 | -1.05% |
| Week 5 | $1.32 | $1.66 | $2.09 | -1.31% |
| Week 6 | $1.29 | $1.65 | $2.13 | -1.57% |
| Week 7 | $1.26 | $1.65 | $2.16 | -1.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation.
Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Gain Therapeutics, Inc. (GANX) is a biotechnology company whose current price is $1.69. Its market capitalization stands at $72.09M, and it is ranked 4353 by market cap size. The asset shows a potential price path outlined in its year-by-year forecast, with 2026 currently around the same level as today and bullish upside developing into the late 2020s and beyond.
The forecast projects a max price of $30.18 by 2050 and an average of $14.08 in 2050, with a long-run bullish stance evident in multiple years.
A major floor 17.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (3.0% away) — a key level to hold.
The nearest ceiling, 20.8% above — a clean break opens room to run.
A major ceiling 29.8% above — clearing it would confirm fresh momentum.
Key GANX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GANX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.74 | Sell | $1.73 | Sell |
| MA 10 | $1.76 | Sell | $1.75 | Sell |
| MA 20 | $1.76 | Sell | $1.76 | Sell |
| MA 50 | $1.79 | Sell | $1.80 | Sell |
| MA 100 | $1.88 | Sell | $1.89 | Sell |
| MA 200 | $2.19 | Sell | $2.00 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.71 | Neutral |
| Stoch RSI (14) | 35.92 | Neutral |
| CCI (20) | -85.30 | Neutral |
| Williams %R (14) | -78.26 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 0.00 | Neutral |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 21.74 | Neutral |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 39.32 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.70 | Sell |
| ADX (14) | 9.56 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is neutral overall. The RSI14 is 40, indicating modest momentum without an overbought or oversold condition. The stock is trading below the SMA50 of $1.78 and below the SMA200 of $2.20, suggesting near-term consolidation around the current price rather than a clear breakout.
Support sits at $1.63 and resistance at $2.03, providing a defined trading range near the current levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $1.68 | $1.99 | 0% | Neutral | |
| $1.35 | $1.76 | $2.45 | +4% | Neutral | |
| $1.33 | $1.80 | $2.64 | +7% | Neutral | |
| $1.44 | $2.03 | $3.10 | +21% | Bullish | |
| $1.82 | $2.64 | $4.16 | +57% | Bullish | |
| $2.15 | $3.21 | $5.21 | +91% | Bullish | |
| $2.25 | $3.45 | $5.73 | +105% | Bullish | |
| $2.08 | $3.28 | $5.56 | +95% | Bullish | |
| $2.15 | $3.48 | $6.02 | +107% | Bullish | |
| $2.30 | $3.81 | $6.73 | +127% | Bullish | |
| $3.41 | $6.30 | $12.03 | +275% | Bullish | |
| $6.07 | $13.48 | $28.79 | +702% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.59 | $1.68 | $1.98 | +0.00% |
| September 2026 | $1.32 | $1.59 | $1.96 | -5.62% |
| October 2026 | $1.34 | $1.62 | $2.04 | +2.37% |
| November 2026 | $1.32 | $1.61 | $2.05 | -0.79% |
| December 2026 | $1.26 | $1.54 | $1.99 | -4.14% |
Click any year to see its month-by-month GANX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GANX price prediction for 2026 points to an average of $1.68 (low $1.59, high $1.99) — a potential gain of 0% on today's $1.68. A consolidation phase looks the most probable path here.
In 2027, GANX is projected to trade between $1.35 and $2.45, averaging $1.76 — a potential gain of +4% from today's $1.68. That is up +4% on the projected 2026 average. Price action looks broadly range-bound.
Gain Therapeutics, Inc.'s 2028 outlook centres on $1.80, within a $1.33 to $2.64 range. That is up +3% on the projected 2027 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, GANX could reach as high as $3.10, with a base case around $2.03 and support toward $1.44 — roughly +21% from $1.68. Momentum favours further upside here.
Expect GANX to range from $1.82 to $4.16 through 2030. The $2.64 average target implies a +57% move from current prices. That is up +30% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The GANX price prediction for 2031 points to an average of $3.21 (low $2.15, high $5.21) — a potential gain of +91% on today's $1.68. Momentum favours further upside here.
In 2032, GANX is projected to trade between $2.25 and $5.73, averaging $3.45 — a potential gain of +105% from today's $1.68. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Gain Therapeutics, Inc.'s 2033 outlook centres on $3.28, within a $2.08 to $5.56 range. That is -5% versus the projected 2032 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2034, GANX could reach as high as $6.02, with a base case around $3.48 and support toward $2.15 — roughly +107% from $1.68. Buyers look set to stay in control over this stretch.
Expect GANX to range from $2.30 to $6.73 through 2035. The $3.81 average target implies a +127% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The GANX price prediction for 2040 points to an average of $6.30 (low $3.41, high $12.03) — a potential gain of +275% on today's $1.68. Buyers look set to stay in control over this stretch.
In 2050, GANX is projected to trade between $6.07 and $28.79, averaging $13.48 — a potential gain of +702% from today's $1.68. That is up +114% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GANX today (≈ 595.238095 GANX) could be worth
$8,023.51
+$7,023.51 (+702%) by 2050 · US Dollar
Based on the average projected GANX price of $13.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GANXwould be worth at today's price.
$1,000 invested in GANX on Jul 31, 2025 (≈ 684.931489 GANX) would be worth
$1,150.68
+$150.68 (+15.1%) today · 1.15× · US Dollar
Based on a GANX entry price of $1.46 vs. today's $1.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.75 | $960 | -4.0% |
| 1 month ago | $1.99 | $844.22 | -15.6% |
| 3 months ago | $1.88 | $893.62 | -10.6% |
| 6 months ago | $1.78 | $943.82 | -5.6% |
| 1 year ago | $1.46 | $1,150.68 | +15.1% |
| All time (5.0y) ago | $8 | $210 | -79.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GANX forecast.
Our base-case forecast reaches $3.40 around 2032.
Implied market cap at $3.40: $145.02M
The multi-year forecast shows a shift to bullish sentiment from 2029 onward, with a progressive rise in expected averages. In 2029 the avg price is $2.07 with a min of $1.47 and a max of $3.16, and a ROI of 22.3. By 2030 the avg rises to $2.74 with a min of $1.88 and a max of $4.32, and a ROI of 62.1.
The trajectory continues higher in 2031 ($3.29 avg), 2032 ($3.53 avg), 2033 ($3.38 avg), 2034 ($3.56 avg), and 2035 ($3.95 avg), with ROIs ranging up to 133.6. The forecast extends to 2040 with an avg of $6.50, a max of $12.45, and an ROI of 284.6, followed by 2050 with an avg of $14.08, a max of $30.18, a min of $6.34, and an ROI of 733.1, all labeled bullish. These estimates imply meaningful upside potential yet remain subject to uncertainty and market volatility.
Tap a question to reveal the answer.
The forecast shows min $1.88, avg $2.74, max $4.32 with an ROI of 62.1 and sentiment BULLISH.
The forecast includes neutral in 2026–2028 and bullish from 2029 onward, with rising averages and ROIs up to 733.1 by 2050; these are estimates and not guarantees.
Yes. The 2050 max is $30.18 with an ROI of 733.1 and bullish sentiment.
Current price $1.69; Market cap $72.09M.
2029 min $1.47; avg $2.07; max $3.16; ROI 22.3; sentiment BULLISH.
Gain Therapeutics, Inc. Community Discussion
0Share your Gain Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.